Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAG | P20916 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31695023 | 0.86 | LMNA (0.34) | LMNAKMT2AMETAP2MAG | |
| SCHEMBL13949943 | 0.85 | LMNA (0.35) | LMNAKMT2AMETAP2ALDH1A1BCHE | |
| SCHEMBL30481196 | 0.84 | LMNA (0.34) | LMNAKMT2AMETAP2ALDH1A1BCHE | |
| SCHEMBL25702536 | 0.84 | LMNA (0.34) | LMNAKMT2AMETAP2ALDH1A1BCHE | |
| SCHEMBL30481187 | 0.82 | LMNA (0.33) | LMNAKMT2AMETAP2ALDH1A1 | |
| SCHEMBL13949941 | 0.82 | LMNA (0.33) | LMNAKMT2AMETAP2ALDH1A1 | |
| SCHEMBL26156656 | 0.82 | CD22 (0.34) | LMNAKMT2AMETAP2MAG | |
| SCHEMBL12454167 | 0.81 | NANP (0.31) | — | |
| SCHEMBL17445206 | 0.81 | NANP (0.31) | — | |
| SCHEMBL31695118 | 0.81 | LMNA (0.31) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754192-B2 | Compositions comprising homogeneously glycosylated erythropoietin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | LMNA 1295/4885KMT2A 2426/4885METAP2 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.